SLC5A2 and type 2 diabetes mellitus: Dapagliflozin therapy was associated with a decreased circulating leptin level and an increased circulating adiponectin level among patients with type 2 diabetes, which, may contribute to the beneficial effects of SGLT2 inhibitors on metabolic homeostasis, such as improved insulin resistance and reduced cardiovascular risk [43,44,45].